Low-dose prednisolone therapy for idiopathic thrombocytopenic purpura

K. Ohmine, T. Izumi, K. Muroi, R. Shimizu, S. Imagawa, N. Komatsu, R. Sasaki, K. Hatake, Y. Miura, K. Ozawa

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Prednisolone (PSL) is widely used for the treatment of idiopathic thrombocytopenic purpura (ITP). We compared the effects of a relatively low dose (0.5 mg/kg/day, LD group) of PSL and the conventional dose (1.0 mg/kg/day, CD group) on 59 ITP patients. Twenty-six patients were treated with low-dose PSL, and 23 patients with the conventional dose. No statistically significant difference was observed in the complete remission rates for the LD group (35%) and the CD group (39%). However, the mean duration of hospitalization was significantly (p < 0.001) shorter for LD group patients than for patients in the CD group (20 days versus 50 days, respectively). In conclusion, low-dose PSL may be as effective as the conventional dose and capable of reducing the cost of hospitalization, thus, improving the quality of life for patients with ITP.

Original languageEnglish
Pages (from-to)8-11
Number of pages4
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Issue number1
Publication statusPublished - 2000 Jan


Dive into the research topics of 'Low-dose prednisolone therapy for idiopathic thrombocytopenic purpura'. Together they form a unique fingerprint.

Cite this